ArticleThe Journal of experimental medicine2007
Hormonal control of the renal immune response and antibacterial host defense by arginine vasopressin.
Article in The Journal of experimental medicine, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 70 citations in OpenAlex.
- Vasopressin compared with norepinephrine augments the decline of plasma cytokine levels in septic shock.American journal of respiratory and critical care medicine · 2013Trial
- Arginine vasopressin (AVP) treatment increases the expression of inhibitory immune checkpoint molecules in monocyte-derived dendritic cells.Immunologic research · 2024Article
- Current and emerging strategies to curb antibiotic-resistant urinary tract infections.Nature reviews. Urology · 2024Review
- Collecting Duct Pro(Renin) Receptor Contributes to Unilateral Ureteral Obstruction-Induced Kidney Injury via Activation of the Intrarenal RAS.Hypertension (Dallas, Tex. : 1979) · 2024Article
- Insulin receptor orchestrates kidney antibacterial defenses.Proceedings of the National Academy of Sciences of the United States of America · 2024Article
- TNF inhibits AQP2 expression via a miR137-dependent pathway.American journal of physiology. Renal physiology · 2024Article
- Uropathogen and host responses in pyelonephritis.Nature reviews. Nephrology · 2023Review
- Arginine vasopressin and pathophysiology of COVID-19: An innovative perspective.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2021Review
- Metabolic acidosis exacerbates pyelonephritis in mice prone to vesicoureteral reflux.Physiological reports · 2020Article
- Involvement of Vasopressin in the Pathogenesis of Pulmonary Tuberculosis: A New Therapeutic Target?Frontiers in endocrinology · 2019Article
- Androgen exposure potentiates formation of intratubular communities and renal abscesses by Escherichia coli.Kidney international · 2018Article
- Cyclosporine A Induces MicroRNAs Controlling Innate Immunity during Renal Bacterial Infection.Journal of innate immunity · 2018Article
- Hypoglycemic activity and constituents analysis of blueberry (Diabetes, metabolic syndrome and obesity : targets and therapy · 2018Article
- Effects of Arginine Vasopressin on Migration and Respiratory Burst Activity in Human Leukocytes.Open medicine (Warsaw, Poland) · 2018Article
- Impaired AQP2 trafficking in Fxyd1 knockout mice: A role for FXYD1 in regulated vesicular transport.PloS one · 2017Article
- The nature of immune responses to urinary tract infections.Nature reviews. Immunology · 2015Review
- A review of the nonpressor and nonantidiuretic actions of the hormone vasopressin.Frontiers in medicine · 2015Review
- Article
- Vasopressin: a novel target for the prevention and retardation of kidney disease?Nature reviews. Nephrology · 2013Review
- Cyclosporine A impairs nucleotide binding oligomerization domain (Nod1)-mediated innate antibacterial renal defenses in mice and human transplant recipients.PLoS pathogens · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 6 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ascending urinary tract infection (UTI) and pyelonephritis caused by uropathogenic Escherichia coli (UPEC) are very common infections that can cause severe kidney damage. Collecting duct cells, the site of hormonally regulated ion transport and water absorption controlled by vasopressin, are the preferential intrarenal site of bacterial adhesion and initiation of inflammatory response. We investigated the effect of the potent V2 receptor (V2R) agonist deamino-8-D-arginine vasopressin (dDAVP) on the activation of the innate immune response using established and primary cultured collecting duct cells and an experimental model of ascending UTI. dDAVP inhibited Toll-like receptor 4-mediated nuclear factor kappaB activation and chemokine secretion in a V2R-specific manner. The dDAVP-mediated suppression involved activation of protein phosphatase 2A and required an intact cystic fibrosis transmembrane conductance regulator Cl- channel. In vivo infusion of dDAVP induced a marked fall in proinflammatory mediators and neutrophil recruitment, and a dramatic rise in the renal bacterial burden in mice inoculated with UPECs. Conversely, administration of the V2R antagonist SR121463B to UPEC-infected mice stimulated both the local innate response and the antibacterial host defense. These findings evidenced a novel hormonal regulation of innate immune cellular activation and demonstrate that dDAVP is a potent modulator of microbial-induced inflammation in the kidney.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.